Zilixir Biotech
Shanghai
About Zilixir Biotech
Zilixir Biotech develops a new protein design technology that offers possibilities for human exploration of the complex life sciences. SWORD™ protein design technology integrates binding pockets, new drug skeleton design, activity prediction, ADME/T prediction, etc., and has had some achievements in these areas, fully demonstrating the effectiveness of protein design.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Total funding: $14.1M
- Funding stage: Early Stage Venture
- Last round: Series A (May 2023)
- Website: zelixir.com
- Phone: 400-687-0908
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Life Science
Canonical: https://fsome.com/organization/zilixir-biotech-10214 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.